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Abstract
In this multicentre study, which is the largest case series ever reported, we aimed to describe the features of tularaemia to provide detailed
information. We retrospectively included 1034 patients from 41 medical centres. Before the definite diagnosis of tularaemia, tonsillitis
(n = 653, 63%) and/or pharyngitis (n = 146, 14%) were the most frequent preliminary diagnoses. The most frequent clinical presentations
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE INFECTIOUS DISEASES
were oropharyngeal (n = 832, 85.3%), glandular (n = 136, 13.1%) and oculoglandular (n = 105, 10.1%) forms. In 987 patients (95.5%), the
lymph nodes were reported to be enlarged, most frequently at the cervical chain jugular (n = 599, 58%), submandibular (n = 401, 39%), and
periauricular (n = 55, 5%). Ultrasound imaging showed hyperechoic and hypoechoic patterns (59% and 25%, respectively). Granulomatous
inflammation was the most frequent histological finding (56%). The patients were previously given antibiotics for 1176 episodes, mostly with
b-lactam/b-lactamase inhibitors (n = 793, 76%). Antituberculosis medications were provided in seven (2%) cases. The patients were given
rational antibiotics for tularaemia after the start of symptoms, with a mean of 26.8  37.5 days. Treatment failure was considered to have
occurred in 495 patients (48%). The most frequent reasons for failure were the production of suppuration in the lymph nodes after the start of
treatment (n = 426, 86.1%), the formation of new lymphadenomegalies under treatment (n = 146, 29.5%), and persisting complaints despite
2 weeks of treatment (n = 77, 15.6%). Fine-needle aspiration was performed in 521 patients (50%) as the most frequent drainage method. In
conclusion, tularaemia is a long-lasting but curable disease in this part of the world. However, the treatment strategy still needs optimization.
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Introduction
Tularaemia is a zoonotic infection caused by Francisella
tularensis, and the disease has been seen in many parts of the
northern hemisphere [1,2]. F. tularensis is a very potent human
pathogen that can produce infection with as few as ten
organisms. The microorganism is highly infectious, and may
enter the human body through the skin after contact with an
infected animal; transmission through the mucosal membranes
of the mouth, throat, eye or bronchus may also occur.
Furthermore, ticks can also transmit the pathogen [3]. The
disease has various clinical presentations, including ulceroglan-
dular, glandular, oculoglandular, oropharyngeal, pneumonic and
typhoidal forms [3]. The ulceroglandular form of the disease
has been reported to be the most common form in the USA
and European countries such as Bulgaria, Hungary, Austria, and
Germany [4,5]. The bacterium is known to persist in water, hay
or mud for weeks, and waterborne epidemics have been
reported in eastern Europe and Turkey [6–9].
F. tularensis ssp. tularensis (type A) and F. tularensis ssp.
holarctica (type B) are the two major subspecies causing human
disease. Type A is considered to be a potential agent of
biological warfare, as it is highly infectious and can cause severe
disease with high fatality rates [10]. On the other hand, type B
causes mild disease with low fatality rates in Europe and Asia,
and is occasionally related to waterborne tularaemia out-
breaks. Both climate change and global warming have been
suggested to have contributed to the spread of the disease
[11]. Recent outbreaks and sporadic case notifications of
tularaemia have been observed in Europe [12]. Sporadic cases
of tularaemia or local outbreaks have been reported since
1936 in Turkey, and the disease has been increasingly seen in
Turkey since 1988 [13]. The clinical manifestations of tular-
aemia have been reported to range from asymptomatic illness
to septic shock [3]. As tularaemia has been known to be
potentially fatal if left untreated [14], proper management of
the disease is of paramount importance for the patient.
There are relatively small case series for tularaemia in the
medical literature detailing the features and the management
issues for the disease. Thus, in this multicentre study, which is
the largest case series ever reported, we aimed to delineate
the potential impacts of this multifaceted disease, and to
provide detailed information concerning the clinical, diagnostic
and therapeutic implications of tularaemia in a region of the
northern hemisphere, Turkey.
Materials and Methods
Study design and patient population
This multicentre study pooled patients with any form of
tularaemia from 41 medical centres in Turkey. The cities of the
participant centres are shown in Fig. 1. The study had a
retrospective design, and included patients treated between
2000 and 2013. No control groups were included for this
study. Fatih Sultan Mehmet Training and Research Hospital’s
Review Board in Istanbul approved the study.
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Microbiological, serological, PCR and other routine test
methods
Blood and serum samples, throat swabs and lymph node
aspirates were used for laboratory diagnosis of tularaemia.
Cultures. Clinical specimens, including throat, conjunctival and
wound swabs, and/or lymph node aspirates, were cultured on
antibiotic-supplemented Cysteine Heart Agar Base with sheep
blood agar (8%) plates (VCNT inhibitor, REF 212408; Becton
Dickinson and Company, Sparks, MD, USA) or blood agar
supplemented with 1% glucose, 0.1% cystine and 100 000 U/
mL penicillin plates, and incubated at 37°C with 5% CO2 for
10 days. Francisella colonies were diagnosed by the use of an
agglutination test with specific antibody (F. tularensis Anti-
serum; BD, Sparks, MD, or Difco, Detroit, MI, USA) and then
PCR.
Agglutination test
A microagglutination test (MAT) was performed with a
commercial antigen as described by the manufacturer (BD
F. tularensis Antigen; Becton Dickinson, Sparks, MD, USA) or
with a home-made F. tularensis antigen obtained from the strains
isolated frompatients with tularaemia in Turkey. In the presence
of compatible symptoms, sustained high titres of 1/160 or
greater in the sera were accepted as indicating a presumptive
diagnosis of tularaemia. For definitive serological diagnosis of all
cases, sera were sent to the reference laboratories in Bursa and
in Ankara by the local health directorates. At the beginning of
2005, a new and completely revised communicable disease
notification was launched nationwide in Turkey, and tularaemia
was given notifiable status in Turkey [15].
ELISA. An anti-F. tularensis ELISA test kit (Seramun, Wolzig,
Germany) was used [16].
PCR analysis. Primer and probe sets targeting ISFtu2 were used
for Real Time TaqMan PCR analysis as described previously.
Reactions were performed in 25-µL volumes containing 2 µL
of sample DNA. TaqMan PCR conditions were as follows:
activation for one cycle at 95°C for 3 min, and amplification
and detection for 40 cycles at 94°C for 10 s and 65°C for 30 s.
In this study, both negative and positive controls (10-fold
dilutions of F. tularensis ssp. holarctica NCTC 10857) were used
in terms of quality assurance [17].
In all patients, a complete blood cell count was performed,
and the erythrocyte sedimentation rate (ESR) was measured
by the Westergren method and the C-reactive protein (CRP)
level by the nephelometric method in blood samples.
Inclusion criteria
Only adult patients treated for tularaemia and aged >17 years
were enrolled. The laboratory diagnosis of tularaemia was
established by one of the following: (i) isolation of F. tularensis
from the clinical specimens; (ii) positive PCR test result; (iii)
positive ELISA result; or (iv) a MAT or tube agglutination test
titre of ≥1/160 or a four-fold increase in the MAT or tube
agglutination test titres within 2 weeks.
Treatment
The patients were treated randomly with one of the
antimicrobial regimens, including parenteral streptomycin
(15 mg/kg daily) or gentamicin (5 mg/kg daily), oral doxy-
cycline (2 9 100 mg), or tetracycline (4 9 500 mg), or cipro-
floxacin (2 9 500 mg), or moxifloxacin (1 9 500 mg) or
combined or sequential drug regimens with these antibiotics.
Definitions
Standard definitions were used for leukopenia, leukocytosis,
and ESR [18,19].
Inadequate medical treatment. Poor compliance with therapy,
irrational antibiotic use for tularaemia and inadequate doses and
duration of rational antibiotics were placed in this category.
Therapeutic failure. The presence of at least one of the
following was considered to indicate therapeutic failure: (i)
the absence of a decrease in fever in a minimum period of 72 h
despite rational treatment, or recurrence of fever in the
FIG. 1. The cities of the participant
centres.
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course of therapy; (ii) persistence of constitutional symptoms
(sore throat, conjunctivitis, fatigue, myalgia, and other com-
plaints) related to tularaemia despite adequate medical treat-
ment; (iii) unresolved complaints despite 2 weeks of medical
treatment; (iv) absence of shrinkage in the lymph nodes despite
medical treatment; (v) the appearance of new lymphadeno-
megaly or lymphadenomegalies in a patient under treatment;
(vi) the occurrence of lymph node suppuration and/or abscess
formation after the start of treatment; and (vii) the absence of
decreases in the blood leukocyte count, serum CRP level and
ESR despite medical treatment.
Relapse. Relapse was defined as the reappearance of clinical
signs and symptoms of tularaemia after the end of treatment.
Ultrasonography (US) investigations
The US investigations were performed by the experienced
radiologists in the participant centres with 7.5–12-MHz linear
transducers. The morphology of the enlarged lymph nodes
(long axis to short axis diameter ratios) and echo character-
istics were determined and recorded for each patient. Data on
colour Doppler US and power Doppler US were not included,
to prevent confusion.
Data collection and statistical methods
A standard questionnaire was sent to the participant centres via
the Internet, and data were collected by use of a computer
database. Demographics, clinical data, including preliminary
diagnosis, the form of tularaemia, comorbid conditions, routine
and tularaemia-specific laboratory analyses, US findings, and
treatment (therapeutic regimens used and surgical operations
performed), and outcome data, including therapeutic failure,
cure, and relapse, were recorded for each patient.
Frequencies and percentages were used for categorical
variables, and mean  standard deviation (range) was used for
continuous variables. Categorical parameters were tested with
Fisher’s exact test or the chi-square test as appropriate.
Numerical data were first tested for normality. Parametric
variables were analysed with Student’s t-test, and non-para-
metric variables were analysed with the Mann–Whitney U-test.
Statistical analysis was performed with standard statistical
software (SPSS version 16.0; SPSS, Chicago, IL, USA). Tests
were two-tailed, and a p-value of <0.05 was considered to be
significant.
Results
In this study, the mean age of the patients was
41.21  16.70 years, and 588 of 1034 patients were females
(57%). The patients were more likely to live in rural areas
(n = 737, 71%) than in urban centres (n = 297, 29%) The
distribution of the occupations was as follows: farmers, 483
(47%); housewives involved in daily agricultural activities, 266
(26%); students, 51 (5%); workers, 32 (3%); shepherds, 30
(3%); hunters, 22 (2%); government employees, 21 (2%);
retired personnel, 18 (2%); soldiers, five (0.4%); foresters, four
(0.3%); veterinarians, three (0.2%); and miscellaneous, 104
(10%).
Preliminary diagnoses
Before the definite diagnosis of tularaemia, the preliminary
diagnoses were as follows: tonsillitis in 653 patients (63%) and/
or pharyngitis in 146 (14%); unspecified lymphadenopathy in
132 (13%); conjunctivitis in 19 (2%); tuberculous lymphade-
nopathy in 19 (2%); abscess formation in 16 (2%); mumps/
parotitis in 14 (1.4%); upper respiratory system infections in 13
(1%); influenza in 13 (1%); malignancy in 11 (1%); deep neck
infections in seven (1%); and thyroiditis in three (0.2%).
Symptoms and findings
The complaints and the findings of the patients are shown in
Table 1. In 987 patients (95.5%), the lymph nodes were
reported to be enlarged. The most frequently involved site was
the cervical lymphatic system, which included the jugular,
submandibular, occipital and preauricular chains. The distribu-
tion of enlarged lymph nodes is shown in Table 2. One-hun-
dred and three skin lesions were detected in 101 (10%)
patients. The distribution of skin eruptions was as follows:
maculopapular, 33; erythema multiforme, 32; erythema nodo-
sum, 30; papular, three; erythematous, two; vesicular, one;
pustular, one; and Sweet syndrome, one.
Laboratory test results
F. tularensis was recovered from culture specimens from 149
patients (14%). The distribution of cultures in which the
microorganism was isolated was as follows: 68 blood cultures,
45 lymph node aspirate cultures, 44 throat cultures, and three
conjunctival cultures. The diagnosis was established with the
MAT in 980 cases (95%), and with tube agglutination in 54 (1%)
cases. The distribution of agglutination test titres is shown in
Fig. 2. PCR provided the diagnosis in 440 (40%) patients, and
ELISA was performed in only eight (1%) patients, all of whom
were positive. An increased ESR was found in 754 of 903
patients (83%) tested. In 23 (3%) patients, the ESR was
>100 mm/h. Serum CRP levels increased in 763 of 905 patients
(84%) tested (>1 mg/dL). Leukocytosis was detected in 272
(29%) of 923 patients tested. The leukocyte count was within
the normal range in 650 (70%) cases, and leukopenia was found
in only one patient (0.1%).
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Previous treatments
In this study, 212 (20.5%) patients did not receive previous
antibiotics for the treatment of tularaemia. However, the rest
of the patients were given antibiotics for 1176 episodes, which
included a single episode in 468 (45.3%) patients, and a second
episode in 354 (34.2%) patients. In the previous treatment,
b-lactam/b-lactamase inhibitors were given to 793 patients
(76%), clindamycin or metronidazole combined with another
antibiotic to 45 (2%), macrolides to seven (0.7%), antituber-
culosis treatment to seven (0.7%), and other antibiotics to 13
(1%).
Specific treatments for tularaemia
The patients were given rational antibiotics for tularaemia after
the start of symptoms with a mean of 26.8  37.5 days
(minimum–maximum, 1–135 days; median, 21 days). The anti-
biotic choices are shown in Table 3. In this cohort, 713
patients were given single antibiotics, 299 patients were given
combination regimens, and 11 patients were given sequential
therapy. For 11 patients, data on the antibiotic choices were
TABLE 2. The results of lymph node investigations
Lymphadenopathy location
(n = 987, 95%) Right/left (%/%) Bilateral (%)
Cervical (n = 599, 61%) 365/359 (37/36) 125 (13)
Submandibular (n = 401, 41%) 270/220 (27/22) 89 (9)
Periauricular (n = 55, 6%) 33/24 (3/2) 2 (0.2)
Axillary (n = 26, 3%) 14/15 (1/2) 3 (0.3)
Inguinal (n = 7, 1%) 5/5 (1/1) 3 (0.3)
Occipital (n = 5, 1%) 0/5 (0/1) –
Other areas (n = 24, 2%) – –
US pattern (n = 725) n %
Hyperechoic pattern 431 59
Hypoechoic pattern 183 25
No change in echogenicity 43 6
Hypoechoic and hyperechoic pattern 3 0.4
Unknown 33 5
Shape of lymph nodea (n = 825) n %
L/S ratio of <2 (round node) 545 66
L/S ratio of >2 (elongated node) 330 40
Cytology findings (n = 157) n %
Granulomatous inflammation 88 56
Suppurative inflammation 77 49
Caseous necrosis 12 8
Necrosis (without caseification) 12 8
Multinuclear giant cells 11 7
Reactive 5 3
US, ultrasonography; L/S, long axis to short axis diameter.
aUS/computed tomography/magnetic resonance imaging.
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FIG. 2. The distribution of agglutination test titres. MA, microagglu-
tination; TA, tube agglutination.
TABLE 1. Symptoms and findings of patients according to clinical presentation
Total,
n (%)
Oropharyngeal,
n = 832
Glandular,
n = 136
Oculoglandular,
n = 105
Ulceroglandular,
n = 43
Pneumonic,
n = 1
Typhoidal,
n = 1
Symptoms, no. (%)
Lymphadenopathya 987 (95) 758 (91) 129 (95) 94 (90) 40 (93) – –
Fever 883 (85) 746 (90) 83 (61) 91 (87) 34 (79) 1 1
Sore throat 872 (84) 771 (93) 82 (60) 78 (74) 20 (47) – –
Muscle pain 680 (66) 591 (71) 49 (36) 71 (68) 25 (58) 1 1
Conjunctivitis 103 (10) 59 (7) – 100 (95) 2 (5) – –
Headache 43 (4) 25 (3) 15 (11) 9 (9) – – 1
Skin ulcer 41 (4) 30 (4) – 10 (10) 11 (26) – –
Weight loss 35 (3) 25 (3) 11 (8) 7 (7) – – –
Weakness 32 (3) 20 (2) 8 (6) 9 (9) 3 (7) – –
Anorexia 31 (3) 18 (2) 9 (7) 6 (6) 1 (2) – –
Cough 24 (2) 20 (2) 4 (3) 4 (4) – 1 –
Arthralgia 21 (2) 12 (1) 4 (3) 7 (7) 2 (5) – –
Nausea/vomiting 17 (2) 8 (1) 5 (4) 1 (1) 3 (7) – –
Dysphagia 7 (1) 6 (1) 1 (1) – 1 (2) – –
Rash 7 (1) 5 (1) – 1 (1) 1 (2) – –
Sputum 6 (1) 3 (0.3) 3 (2) 1 (1) – 1 –
Oral aphthae 3 (0.2) 3 (0.3) – – – – –
Findings, no. (%)
Fever 76 (7) 66 (8) 2 (1) 5 (5) 3 (7) 1 1
Tonsillopharyngitis 482 (47) 466 (56) – 37 (35) 7 (16) – –
Mucosal membrane 315 (30) 305 (37) – 13 (12) 5 (12) – –
Oral mucosal lesion 53 (5) 51 (6) – 11 (10) 1 (2) – –
Conjunctivitis 56 (5) 26 (3) – 55 (52) – – –
Rash 101 (10) 87 (10) – 14 (13) 10 (2) – –
aDetected by palpation.
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missing from the hospital records. Five of eight pregnant
women were treated with gentamicin. The remaining three
were treated after the delivery.
Therapeutic outcomes
Treatment failure was considered to have occurred in 495
patients (48%). The most frequent reasons for failure were the
production of suppuration in the lymph nodes after the start of
treatment (n = 426, 86.1%), the formation of new lymphad-
enomegalies under treatment (n = 146, 29.5%), and persisting
complaints despite 2 weeks of treatment (n = 77, 15.6%).
Therapeutic failure parameters are shown in Table 4 and
Fig. 3. Lymph nodes were seen to be fistulizing in 108 (10%)
patients on admission. After the start of antibiotics, lymph
node size decreased in 519 patients (50%), lymph nodes were
impalpable in 101 (10%), lymph node size was unchanged in
167 (16%), lymph node size increased in 108 (10%), and lymph
nodes fistulized in 53 (5%) (Fig. 4). The last three parameters
indicated the unresponsiveness of lymph node inflammation to
antibiotic treatment (n = 328, 35%). In this study, lack of
compliance with treatment, leading to persistence of the
complaints, was observed in 15 (1.5%) patients. Other
complications included nephropathy (n = 8, 0.8%), hearing
loss (n = 3, 0.3%), vertigo (n = 2, 0.2%), hepatitis (n = 2,
0.2%), and tinnitus (n = 1, 0.1%). It was not certain whether
these other rare complications were directly related to
tularaemia or were attributable to other reasons. Relapse
was observed in 24 patients (2%). Table 5 shows the antibiotic
choices in patients with relapses. Mortality was not observed.
Surgical procedures
Fine-needle aspiration was performed in 521 patients (50%),
incision and drainage in 121 (12%), and excision of the lymph
node in 36 (3%).
Discussion
This study, the largest case series ever reported, has shown that
tularaemia in Turkey is mostly of the oropharyngeal form. The
presentation of the patient was mostly based on enlarged lymph
nodes (92%), which can be translated as swollen neck along with
fever (85%), and sore throat (84%). However, symptoms and
TABLE 3. Reasons for therapeutic failure after the start of
antibiotics in tularaemia patients
Therapeutic failure
parameters (n = 495)
Overall Monotherapy Combination
n (%) n (%) n (%)
Suppuration of the
lymph nodes
426 (86) 248 (58) 178 (60)
Formation of new
lymphadenopathies
146 (29) 93 (22) 53 (18)
Persisting complaints
despite 2 weeks of
treatment
77 (16) 37 (9) 40 (13)
Absence of shrinkage
in the lymph nodes
63 (13) 45 (10) 18 (6)
Absence of regression
in acute-phase
reactantsa
13 (3) 6 (1) 7 (2)
Unresolving fever for
72 h despite treatment
4 (1) 2 (0.4) 2 (1)
Total 495 431 298
aErythrocyte sedimentation rate, C-reactive protein, leukocytosis.
TABLE 4. Distribution of antibiotics with respect to duration of treatment
Antibiotics n (%) Missing
Treatment duration (days)
<7 7–14 15–21 22–30 >45
Monotherapy, no. (%)
Streptomycin 291 (28) 2 (0.2) – 266 (26) 18 (2) 4 (0.4) 1 (0.1)
Ciprofloxacin 188 (18) – – 141 (14) 47 (5) – –
Doxycycline 127 (12) 2 (0.2) – 41 (4) 80 (8) 2 (0.2) 2 (0.2)
Gentamicin 85 (8) – – – 83 (8) 2 (0.2) –
Moxifloxacin 17 (2) – – 10 (1) 6 (1) 1 (0.1) –
Tetracycline 5 (0.5) 1 (0.1) – – – 1 (0.1) 3 (0.3)
Combination therapy, no. (%)
Streptomycin + doxycycline 104 (10) – – 41 (4) 54 (5) 8 (1) 1 (0.1)
Ciprofloxacin + doxycycline 71 (7) – 1 (0.1) 12 (1) 57 (6) – 1 (0.1)
Gentamicin + doxycycline 30 (3) – – 2 (0.2) 27 (3) 1 (0.1) –
Moxifloxacin + doxycycline 10 (1) – – 1 (0.1) 9 (1) – –
Streptomycin + ciprofloxacin 35 (3) – – 29 (3) 4 (0.4) – 2 (0.2)
Gentamicin + ciprofloxacin 41 (4) – 1 (0.1) 40 (4) – – –
Doxycycline + rifampicin 3 (0.3) – – 1 (0.1) – 2 (0.2) –
Streptomycin + doxycycline +
ciprofloxacin
5 (0.5) – – 2 (0.2) 3 (0.3) – –
Sequential therapy (total days),
no. (%)
Streptomycin–doxycycline 4 (0.4) – – 1 (0.1) 1 (0.1) 2 (0.2) –
Ciprofloxacin–doxycycline 3 (0.3) – – 3 (0.3) – – –
Streptomycin–ciprofloxacin 2 (0.2) – – 1 (0.1) – 1 (0.1) –
Gentamicin–ciprofloxacin 2 (0.2) – – 2 (0.2) – – –
Missing data, no. (%_ 11 (1) 11 (1) – – – – –
Total, no. (%) 1034 (100) 16 (0.5) 2 (0.2) 593 (57) 389 (38) 24 (2) 10 (1)
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findings were seen in a diverse pattern. Waterborne spread is
far more common in Europe and Turkey than in the USA. In
recent Turkish studies, drinking natural spring water was found
to be the leading risk factor for the development of tularaemia
[17,20]. The surveillance of infection has been strengthened in
Turkey since 2004 bymandatory notification of the disease [21],
and cases are now better recognized throughout the country.
Skin rashes were of particular interest, and inconsistent data
were reported in relatively small case series comprising a few
cases with dermatological manifestations [7,22,23]. In our
study, 10% of the patients had skin rashes such as maculopapular
eruptions, erythema multiforme and erythema nodosum as the
most frequent lesions. Accordingly, acute-phase reactant levels
were high in most of our patients. In this study, more
than three-quarters of the patients were found to suffer
from tonsillitis and/or pharyngitis preceding the diagnosis of
tularaemia.
In this study, the US findings of the cervical lymph nodes
were quite non-specific, as they presented as either hyper-
echoic or hypoechoic changes. Focal or diffuse abnormal
(hyperechoic, hypoechoic, or mixed) echo changes of cervical
lymph nodes were found in nearly 85% of our cases with
tularaemia. Being the most prevalent pattern, hyperechoic
changes were probably attributable to increased interfaces of
inflammation, which reflected the sound beam in all directions
[24]. The second form, hypoechogenity, may be related to
necrosis [24,25]. Affected lymph nodes were unilateral in up to
two-thirds of all cases, and long axis to short axis diameter
ratios were preserved in two-thirds of the cases. There are
several small case series in the literature in which the
lymphatic enlargement was unilateral [22,26,27]. The probable
explanation is the high infectivity of the bacterium, as the
present organisms are able, with low bacterial counts, to
invade the oropharyngeal mucosa wherever feasible. Although
variability existed, the mean diameter of the short axes of the
dominant lymph nodes was found to be 1.7 cm and that of the
long axes 3.2 cm in another study [25]. Consequently,
tularaemia must be considered in the differential diagnosis of
a febrile disease with oval or round enlarged cervical lymph
nodes with hypoechoic/hyperechoic cortical changes.
Although the diagnosis in our patients was commonly
established with the MAT, culture was positive in 14% of cases
and PCR disclosed tularaemia in 40% of cases. Despite the
special requirements, such as biosafety level 3 laboratories, for
the culture of F. tularensis [28], the high positivity rate in our
study seems to be directly correlated with the increasing
recognition in the country leading to notable collaboration
with the national reference laboratory. Accordingly, the MAT
was used in 95% of our cases. The probable reasons for the
widespread MAT use were the awareness of tularaemia and
the free-of-charge testing that the government provided.
However, the MAT titres in our patients were very high, with
TABLE 5. Distribution of antibiotics in the patients with
relapses
Antibiotics n (%) Missing
Treatment duration (days)
<7 7–14 15–21 22–30 >45
Monotherapy
Streptomycin 7 – – 5 – 2 –
Ciprofloxacin 2 – – 2 – – –
Doxycycline 1 – – – – 1 –
Gentamicin 2 – – 2 – – –
Combination therapy
Streptomycin +
doxycycline
4 – – 1 – 3 –
Ciprofloxacin +
doxycycline
2 – – 1 1 – –
Gentamicin +
doxycycline
1 – – 1 – – –
Doxycycline +
rifampicin
2 1 – – – 1 –
Streptomycin +
doxycycline +
ciprofloxacin
1 – – – 1 – –
Sequential therapy (total days)
Ciprofloxacin–
doxycycline
1 1 – – – – –
Missing data 1 1 – – – – –
Total 24 3 – 12 2 7 –
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Suppuration
New LAMs
Persisting complaints > 2 weeks
Unresolving fever > 72 h
Persisting LAMs
Persisting inflammatory markers
86%
29%
16%
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FIG. 3. The distribution of therapeutic failure parameters. LAM,
lymphadenomegaly.
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FIG. 4. The course of the enlarged lymph nodes after the start of
antibiotics.
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a mean of 1/640. These exceedingly high titres were probably
attributable to delayed diagnosis of the cases. Maximum
antibody titres are known to occur 6 weeks after the onset of
symptoms, and they decline 2–3 months after treatment [7].
Thus, in a patient with sore throat, fever, and lymphadenop-
athy, the MAT can be easily used in the differential diagnosis of
tularaemia in endemic regions. However, in the first 2 weeks
of infection, MAT titres were reported to be low, and thus the
use of PCR should be considered at the early stages of
tularaemia [2,28,29].
The data related to the histopathological features of
lymphadenomegaly in tularaemia are restricted to small case
series [25,30,31]. Usually, reactive changes without necrosis
have been reported in the early stages. After the second week,
abscess formation with or without epithelioid cell reactions
has been reported. A great number of small epitheloid
granulomas that contain necrosis at the centre appear at
approximately 2–6 weeks, and multinuclear giant cells have
been noted. Finally, caseous necrosis has generally been
detected after the fourth week of disease [32,33]. Tuberculosis
must be kept in mind, particularly in the differential diagnosis
when caseous material exists. When lymph nodes are
inflamed, abscess formation can occur in tuberculous lymph-
adenitis [33]. Thus, in a patient with febrile lymphadenopathy,
the clinical and histopathological assessment of the disease may
be confusing, and may favour tuberculous adenitis. In this
study, 157 patients were evaluated histopathologically. The
most frequent histopathological diagnosis was granulomatous
inflammation (56%), followed by suppurative inflammation in
half of the cases. Caseous necrosis was seen in only 8% of our
patients. Consequently, clinicians have a tendency to manage
febrile patients who are unresponsive to b-lactam antibiotics
with antituberculosis medications in cases of granulomatous or
caseous lymphadenitis [33,34]. As tularaemia can be treated
with antituberculosis drugs such as streptomycin, these
patients can be erroneously treated in favour of tuberculosis
for months. In a large cohort of cervical tuberculosis patients,
7% of the cases were found to be positive for tularaemia with
the MAT [34]. In contrast, 1% of the cases were treated for
tuberculosis in this study. Thus, in countries where tularaemia
is endemic, the disease should be considered primarily in the
differential diagnosis of tuberculosis to prevent irrational
treatment.
Owing to the rapid development of infection in the course
of tularaemia, therapeutic success will depend on early clinical
suspicion and start of therapy [28]. According to the WHO
guideline, the first choices for treatment are bactericidal
antibiotics such as streptomycin or gentamicin for 10 days.
Doxycycline or ciprofloxacin are the alternative choices,
particularly for non-severe cases. When doxycycline is used
as a therapeutic regimen, the duration of treatment should be
15 days, owing to its bacteriostatic nature. Penicillins,
cephalosporins, macrolides, rifampicin, trimethoprim–sulpha-
methoxazole and clindamycin are not effective against F. tular-
ensis, and these drugs should not be used in the management
of tularaemia [http://whqlibdoc.who.int/publications/2007/
9789241547376_eng.pdf]. The antibiotic susceptibility patterns
of F. tularensis in local Turkish studies were in accordance with
these general concepts [35,36]. In this study, three-quarters of
our patients who previously attended health institutions had
used various antibiotics, most frequently b-lactams. It appears
that the diagnosis of the disease is generally delayed. However,
early treatment of the disease is known to result in better
outcomes [25,37], and therapeutic delays exceeding 3 weeks
have resulted in frequent failures [23]. In this study, it took a
mean of 4 weeks to provide rational antibiotics to tularaemia
patients, and early treatment was not always feasible, owing to
the subtle nature of the disease. One of the therapeutic failure
parameters was detected in half of our patients. Consequently,
our data suggested that tularaemia was more severe and more
frequently associated with complications than is commonly
perceived. The most frequent reasons for failure were related
to lymph nodes, such as the absence of shrinkage, suppuration,
and the formation of new lymphadenopathies, despite treat-
ment. Unresolving complaints despite treatment and the
persistence of high levels of inflammatory markers were
relatively rare in this study. However, at the end, although the
use of antibiotics was extended to >2 weeks in one-quarter of
the cases, all of the patients were cured completely. Thus, the
course of the disease was both protracted and related to
therapeutic failures, and, when medical treatment was
extended in combination with surgical procedures, the infec-
tion was completely eradicated even in problematic cases.
According to our data, up to half of the patients with
therapeutic failures were treated with combination regimens,
although combination therapy is not advocated in current
guidelines, other than for particular conditions such as
meningitis and endocarditis. However, the clinicians in this
study probably preferred to use combined antibiotics in hard-
to-treat cases or in patients with extended disease courses
frequently related to therapeutic failures. Accordingly, five
pregnant women were cured with gentamicin in our study, and
there are reports in the literature of the successful use of
gentamicin during pregnancy [38]. Finally, although the relapse
rates were as low as 2% with combined medical and surgical
approaches, some of those who relapsed may have gone to
other centres, and the relapse rate may therefore have been
under-reported.
Controversy still exists regarding the selection of the
drainage procedure. Fine-needle aspiration may have particular
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advantages, as it does not leave scar tissue, in contrast to
incisional drainage or excision. On the other hand, septum
formation of the lymph node may obscure the efficacy of the
method chosen, and further data are needed on this issue. In
this study, the most frequent drainage procedure was
fine-needle aspiration, which was performed in half of all
patients, followed by incision, which was performed in
one-tenth of the cases.
The major limitation of our study was its retrospective
design. However, in this study, which is the largest case series
ever reported, we have presented a wealth of information. In
conclusion, tularaemia is a long-lasting but a curable disease in
this part of the world. Our study indicated that, in our region,
the most common clinical form was oropharyngeal tularaemia.
Cervical lymphadenomegaly was the most common clinical
sign, and granulomatous inflammation of lymph nodes was the
most common histopathological finding. In addition, the most
common complication of oropharyngeal tularaemia was lymph
node suppuration. Hence, the differential diagnosis of tuber-
culosis is an important concern for tularaemia patients. In this
study, the most commonly used antibiotics were streptomycin
and doxycycline. However, the treatment strategy still needs
optimization.
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